ARCHIVES

AVEO’s Tivozanib Sunk by Fundamental Flaw: Higher Overall Survival in the Control Arm

This article is from The Cancer Letter archive.

Vol. 39 No. 18 | May 8, 2013

Download PDF Visit The Full Archive

Related Articles

Addition of Immune Stimulant To Yervoy Therapy Increases Overall Survival, Study Says

November 28, 2014

NCI Still Supporting Construction Grants Despite Big Cuts

February 20, 1981

Evidence Lacking On Value of Vitamins to Prevent Disease, Panel Says.

June 16, 2006

In Brief: NCI Tells Cooperative Groups To Submit applications For Extra Multimodality Funds

November 28, 1975

Duke Promised $11.5M For Eye, Lung Research.

March 8, 2002

The Cancer Letter Wins Investigative Reporting Award

June 8, 2001